| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| ln Vivo |
In a postpartum depression (PPD) mouse model induced by dexamethasone sodium phosphate during pregnancy, oral administration of TB-III (10, 20, 40 mg/kg/day for 7 days) significantly and dose-dependently reduced the immobility time in both the forced swimming test (FST) and tail suspension test (TST), indicating antidepressant-like activity. The effect of 40 mg/kg TB-III was comparable to that of the positive control fluoxetine (10 mg/kg). [1]
Treatment with TB-III (10, 20, 40 mg/kg) significantly reversed the PPD-induced elevation of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in both serum and hippocampal tissues. It also normalized the altered levels of the anti-inflammatory cytokine IL-10 (increased in serum, decreased in hippocampus) in PPD mice. [1] Western blot analysis showed that TB-III treatment (10, 20, 40 mg/kg) significantly upregulated the protein expression levels of brain-derived neurotrophic factor (BDNF), glycogen synthase kinase-3β (GSK-3β), glutamate receptor subunit 1 (GluR1), postsynaptic density protein 95 (PSD95), and synapsin I in the hippocampal tissues of PPD mice, which were downregulated in the model group. [1] |
|---|---|
| Animal Protocol |
A postpartum depression (PPD) mouse model was established by subcutaneous injection of dexamethasone sodium phosphate (0.2 mg/kg/day) to pregnant BALB/c mice from day 15 of pregnancy until parturition. [1]
Postpartum mice with PPD were randomly divided into groups and treated by oral gavage once daily for 7 days. TB-III was dissolved in 0.5% sodium carboxymethyl cellulose (CMC-Na) and administered at doses of 10, 20, and 40 mg/kg. The positive control group received fluoxetine (10 mg/kg, dissolved in 0.5% CMC-Na). The model and normal control groups received the vehicle (0.5% CMC-Na) only. The intragastric volume was 10 ml/kg for all treatments. [1] Behavioral tests (FST and TST) were performed 24 hours after the last drug administration. Subsequently, mice were anesthetized, blood was collected from the abdominal aorta for serum preparation, and hippocampal tissues were dissected for cytokine measurement and protein analysis. [1] |
| References |
|
| Additional Infomation |
It has been reported that thymosin B exists in Anemarrhena asphodeloides, and there are related data reports.
Timosaponin B III (TB-III) is a saponin isolated from the dried rhizome of Anemarrhena asphodeloides Bge. [1] Studies have shown that in a mouse model of postpartum depression (PPD), the antidepressant mechanism of TB-III involves regulating peripheral and central inflammatory responses, activating the BDNF/GSK-3β signaling pathway in the hippocampus, and promoting synaptic plasticity by upregulating key synaptic proteins (GluR1, PSD95, synaptic protein I). [1] |
| Molecular Formula |
C45H74O18
|
|---|---|
| Molecular Weight |
903.06
|
| Exact Mass |
902.487
|
| CAS # |
142759-74-8
|
| PubChem CID |
44575944
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
1023.7±65.0 °C at 760 mmHg
|
| Flash Point |
572.9±34.3 °C
|
| Vapour Pressure |
0.0±0.6 mmHg at 25°C
|
| Index of Refraction |
1.626
|
| LogP |
2.01
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
18
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
63
|
| Complexity |
1590
|
| Defined Atom Stereocenter Count |
25
|
| SMILES |
CC1=C(O[C@@H]2[C@H]1[C@]3(CC[C@H]4[C@H]([C@@H]3C2)CC[C@H]5[C@@]4(CC[C@@H](C5)O[C@H]6[C@@H]([C@H]([C@H]([C@H](O6)CO)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)C)C)CC[C@H](C)CO[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O
|
| InChi Key |
ROHLIYKWVMBBFX-XNZAAYBPSA-N
|
| InChi Code |
InChI=1S/C45H74O18/c1-19(18-57-41-38(55)35(52)32(49)28(15-46)60-41)5-8-26-20(2)31-27(59-26)14-25-23-7-6-21-13-22(9-11-44(21,3)24(23)10-12-45(25,31)4)58-43-40(37(54)34(51)30(17-48)62-43)63-42-39(56)36(53)33(50)29(16-47)61-42/h19,21-25,27-43,46-56H,5-18H2,1-4H3/t19-,21+,22-,23+,24-,25-,27-,28+,29+,30+,31-,32+,33+,34-,35-,36-,37-,38+,39+,40+,41+,42-,43+,44-,45-/m0/s1
|
| Chemical Name |
(2R,3R,4S,5S,6R)-2-[(2S)-4-[(1R,2S,4S,8S,9S,12S,13S,16S,18R)-16-[(2R,3R,4S,5R,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-7,9,13-trimethyl-5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-6-en-6-yl]-2-methylbutoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~110.73 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (2.77 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.1073 mL | 5.5367 mL | 11.0735 mL | |
| 5 mM | 0.2215 mL | 1.1073 mL | 2.2147 mL | |
| 10 mM | 0.1107 mL | 0.5537 mL | 1.1073 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
